Report Content
- Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
- Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
- Executive Summary
- Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter's Five Force Analysis
- Biosimilars Market, By Applications
5.1 Introduction
5.2 Oncology
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Chronic and autoimmune disorders
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Growth hormonal deficiency
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Blood disorders
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 Others
5.6.1 Market Overview
5.6.2 Market Size and Forecast
- Biosimilars Market, By Product Class
6.1 Introduction
6.2 Immunomodulators
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Anti-inflammatory Agents
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Others
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Recombinant Hormones
6.5.1 Market Overview
6.5.2 Market Size and Forecast
6.6 Monoclonal Antibodies
6.6.1 Market Overview
6.6.2 Market Size and Forecast
- Biosimilars Market, By Geography
7.1 Introduction
7.2 Europe
7.2.1 Europe Market, By Applications
7.2.2 Europe Market, By Product Class
7.3 North America
7.3.1 North America Market, By Applications
7.3.2 North America Market, By Product Class
7.4 Asia Pacific
7.4.1 Asia Pacific Market, By Applications
7.4.2 Asia Pacific Market, By Product Class
7.5 Rest of The World
7.5.1 Rest of The World Market, By Applications
7.5.2 Rest of The World Market, By Product Class
- Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
- Company Profiles
9.1 Samsung Bioepis Co. Ltd
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Stada Arzneimittel AG
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Teva Pharmaceutical Industries Ltd
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Intas Pharmaceuticals Ltd
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 LG Life Sciences
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Pfizer Inc
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 Eli Lilly and Company
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
9.8 Celltrion Healthcare
9.8.1 Company Overview
9.8.2 Product/Service Landscape
9.8.3 Financial Overview
9.8.4 Recent Developments
9.9 Mylan NV
9.9.1 Company Overview
9.9.2 Product/Service Landscape
9.9.3 Financial Overview
9.9.4 Recent Developments
9.10 Novartis AG
9.10.1 Company Overview
9.10.2 Product/Service Landscape
9.10.3 Financial Overview
9.10.4 Recent Developments